Peter Libby and his collaborators focused on the potential value of using IL-1β as a treatment target for atherosclerosis, including performing biomarker-directed application of an anti-inflammatory strategy and personalized allocation of therapy for cardiovascular patients (55, 56). This evidence concerns the gene IL1B and atherosclerosis.